As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Biostem Technologies, Inc. The largest reported stake is The PNC Financial Services Group, Inc.'s, at 10.4%. One filing is on record since November 5, 2026 (Schedule 13G, November 5, 2026).
Sell to companies like Biostem Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: The PNC Financial Services Group, Inc. · Sole voting: 1,941,390 · Shared voting: 0 · Sole dispositive: 793,847 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
- · Holder: The PNC Financial Services Group, Inc. · Percent: 10.4% · SCHEDULE 13G
- · Holder: The PNC Financial Services Group, Inc. · Percent: 10.4% · Shares: 1,941,390 · SCHEDULE 13G
Biostem Technologies, Inc. has 1 Schedule 13D or 13G filing on record since 2026-11-05. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| The PNC Financial Services Group, Inc. | 10.4% | 1,941,390 | SCHEDULE 13G, 2026-11-05 | 2026-10-31 |
Holding shares or following this stake? See who's behind Biostem Technologies, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Biostem Technologies, Inc. and the records around it.
Biostem Technologies, Inc. elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Form D filing Jun 2026
- Who owns it
Companies that share a holder
- The PNC Financial Services Group, Inc. also filed stake reports on 9 other companies: Avantis US Large Cap Value ETF (Nov 2026), Invesco China Technology ETF (Nov 2026), Global X Artificial Intelligence & Technology ETF (Aug 2026)
Watch Biostem Technologies, Inc.
Get an email when Biostem Technologies, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Biostem Technologies, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Biostem Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biostem Technologies, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| The PNC Financial Services Group, Inc. | 1,941,390 | 0 | 793,847 | 0 | SCHEDULE 13G, 2026-11-05 |
The latest filing identifies Biostem Technologies, Inc. by CUSIP 090684200 and gives its principal executive office as 2836 Center Port Circle, Pompano Beach, FL 33604 (SCHEDULE 13G, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-11-05 | The PNC Financial Services Group, Inc. | 10.4% | SCHEDULE 13G |
Also on the record for Biostem Technologies, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 9, 2026 | Form D, private offering | $3M sold | Form D page | Source |
| June 3, 2026 | Form D, private offering | $2.50M sold | Form D page | Source |
| December 1, 2020 | Court case: ChenMed, LLC v. Biostem Technologies, Inc., District Court, S.D. Florida | — | Court records | Source |
Biostem Technologies, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for Biostem Technologies, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.